Case updates
A June 4, 2026 order grouped Dupixent skin cancer cases in New Jersey. A shared case group does not decide your claim or promise payment.
Updated Oct 4, 20268 sources
See If You Qualify
Free · No obligation · About 2 minutes
Updated Oct 4, 20268 sources
This may apply to you if
These are cited sources. Their inclusion does not imply that they endorse People’s Justice or reviewed this page.
Matthew F. Kennelly · United States Judicial Panel on Multidistrict Litigation · Acting Chair, Judicial Panel on Multidistrict Litigation
Finding: Transferred listed CTCL actions to New Jersey under Judge Zahid N. Quraishi for coordinated pretrial proceedings; causation and warning adequacy remain disputed questions.
Dupixent JPML transfer order, June 4, 2026 (opens in a new tab) · Jun 4, 2026 · Checked Oct 3, 2026
Thomas Jefferson University · Dermatologic Therapy · 2024
Read the source: Increased Risk of Cutaneous T-Cell Lymphoma Development after Dupilumab Use for Atopic Dermatitis (opens in a new tab) · Checked Oct 3, 2026
The process
You answer a few questions
About two minutes. Nothing is sent until you agree on the last step and press submit.
A lawyer looks at it
A lawyer at the firm reads your answers and checks them against the current case criteria.
The firm decides and gets in touch
If the firm takes your case, you get the terms in writing to read before you sign. You can always say no.
The June 4 order sent listed Dupixent cancer cases to New Jersey for shared pretrial work. It did not decide whether the drug caused the cancer.
Judge Zahid N. Quraishi was assigned the cases. The group is MDL 3180, meaning a federal group of separate cases with common questions. Your own claim still needs its facts checked.
The transfer date is not a personal filing deadline. Ask a lawyer which time limit applies to your claim and whether another court date affects it.
Use your treatment and diagnosis dates for that discussion. A court schedule for an existing case and the time to start a new claim are different questions.
The June order listed 15 cases and seven more that might join. They were in 12 court districts. This is not today’s total.
The order's list identifies the actions it addressed. Some were transferred from outside New Jersey. Ask for a dated court record before relying on a later case-count claim.
On June 4, 2026, the panel sent the listed cases to New Jersey. It left other types of T-cell cancer for later case-by-case checks.
The order describes CTCL, a skin T-cell cancer, in the claims before it. It does not include every illness after Dupixent merely because the same medicine was used.
The court grouped shared questions about cause and warnings. Grouping cases is not an answer to those questions and is not a trial result.
A 2024 record study found more skin T-cell cancer diagnoses in treated eczema patients than in matched untreated patients. It cannot establish a personal cause. Shared research may matter to litigation without deciding one person's medical history.
Keep your case number if you have one, and ask which court issued the update. For a new claim, start with your drug and diagnosis dates.
Request missing health records from the treating office; the federal access rule has stated limits. Ask the lawyer to explain fees and expenses in writing before agreeing to representation.
The model fee rule describes what a contingent agreement should explain, including percentages and expenses. It is not a statement of any firm's actual terms or a promise that first contact is free.
Follow this case
One email when something changes: a ruling, a deadline, a settlement step. Nothing else.
The review is free and private. Asking for it doesn’t commit you to anything.
Register your interestChecked against 8 primary sources by People's Justice editors · Updated
How we make moneyPeople's Justice research team · Updated Oct 4, 2026